文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

西罗莫司加入标准环孢素+霉酚酸酯方案预防非清髓无关供者HSCT后GVHD

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2019-06-24

这项多中心随机3期试验在168例接受非清髓HLA相合无关供者HSCT的患者中,比较标准环孢素+霉酚酸酯方案与加用西罗莫司的三药方案。

要点

  • 3-4级急性GVHD和慢性GVHD累积发生率两组无显著差异。

核心结论

  • 在环孢素+霉酚酸酯基础上加用西罗莫司可显著降低非清髓HLA相合无关供者HSCT后第100天2-4级急性GVHD累积发生率。
  • 基于该结果,环孢素+霉酚酸酯+西罗莫司已成为Fred Hutchinson癌症研究中心该类患者新的标准GVHD预防方案。

研究设计与样本

  • 多中心、随机、3期试验,在美国、丹麦和德国的9个HSCT中心开展。
  • 纳入晚期血液系统恶性肿瘤、Karnofsky评分≥60、年龄>50岁或≤50岁但被认为高剂量预处理相关毒性高风险的患者。
  • 采用按移植中心分层的适应性随机化,分配至标准GVHD预防组(环孢素+霉酚酸酯)或三药组(环孢素+霉酚酸酯+西罗莫司),患者和医生未设盲。
  • 共180例入组,167例接受完整研究干预并纳入安全性和有效性分析:标准组77例,三药组90例。
  • 因预设无效性中期分析结果,数据与安全监察委员会于2016年7月27日建议提前终止研究。

关键数值与推荐

  • 预处理:氟达拉滨30 mg/m2/天,移植前第4、3、2天;移植当天(第0天)接受2或3 Gy全身照射。
  • 标准组霉酚酸酯:从第0天起口服15 mg/kg每日三次至第30天,之后每日两次至第150天,无GVHD情况下至第180天逐渐停用。
  • 三药组霉酚酸酯剂量同标准组,但于第40天停用;西罗莫司从移植前3天开始口服2 mg每日一次,调整谷浓度至3-12 ng/mL,持续至第150天,无GVHD情况下至第180天逐渐停用。

临床怎么用

  • 对于接受非清髓预处理HLA相合无关供者HSCT的患者,可考虑在环孢素+霉酚酸酯基础上加用西罗莫司预防急性GVHD。
  • 西罗莫司需调整谷浓度至3-12 ng/mL,霉酚酸酯在三药方案中于第40天停用。
  • 两组最常见的CTCAE 4级或以上毒性反应为肺部毒性。

局限性

  • 研究因预设无效性中期分析结果而提前终止。
  • 患者和医生未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute graft-versus-host-disease (GVHD) after non-myeloablative human leucocyte antigen (HLA)-matched, unrelated donor, allogeneic haemopoietic stem cell transplantation (HSCT) is associated with considerable morbidity and mortality. This trial aimed to evaluate the efficacy of adding sirolimus to the standard cyclosporine and mycophenolate mofetil prophylaxis therapy for preventing acute GVHD in this setting. METHODS: This multicentre, randomised, phase 3 trial took place at nine HSCT centres based in the USA, Denmark, and Germany. Eligible patients were diagnosed with advanced haematological malignancies treatable by allogeneic HSCT, had a Karnofsky score greater than or equal to 60, were aged older than 50 years, or if they were aged 50 years or younger, were considered at high risk of regimen-related toxicity associated with a high-dose pre-transplantation conditioning regimen. Patients were randomly allocated by an adaptive randomisation scheme stratified by transplantation centre to receive either the standard GVHD prophylaxis regimen (cyclosporine and mycophenolate mofetil) or the triple-drug combination regimen (cyclosporine, mycophenolate mofetil, and sirolimus). Patients and physicians were not masked to treatment. All patients were prepared for HSCT with fludarabine (30 mg/m2 per day) 4, 3, and 2 days before receiving 2 or 3 Gy total body irradiation on the day of HSCT (day 0). In both study groups, 5·0 mg/kg of cyclosporine was administered orally twice daily starting 3 days before HSCT, and (in the absence of GVHD) tapered from day 96 through to day 150. In the standard GVHD prophylaxis group, 15 mg/kg of mycophenolate mofetil was given orally three times daily from day 0 until day 30, then twice daily until day 150, and (in the absence of GVHD) tapered off by day 180. In the triple-drug group, mycophenolate mofetil doses were the same as in the standard group, but the drug was discontinued on day 40. Sirolimus was started 3 days before HSCT, taken orally at 2 mg once daily and adjusted to maintain trough concentrations between 3-12 ng/mL through to day 150, and (in the absence of GVHD) tapered off by day 180. The primary endpoint was the cumulative incidence of grade 2-4 acute GVHD at day 100 post-transplantation. Secondary endpoints were non-relapse mortality, overall survival, progression-free survival, cumulative incidence of grade 3-4 acute GVHD, and cumulative incidence of chronic GVHD. Efficacy and safety analyses were per protocol, including all patients who received conditioning treatment and underwent transplantation. Toxic effects were measured according to the Common Terminology Criteria for Adverse Events (CTCAE). The current study was closed prematurely by recommendation of the Data and Safety Monitoring Board on July 27, 2016, after 168 patients received the allocated intervention, based on the results of a prespecified interim analysis for futility. This study is registered with ClinicalTrials.gov, number NCT01231412. FINDINGS: Participants were recruited between Nov 1, 2010, and July 27, 2016. Of 180 patients enrolled in the study, 167 received the complete study intervention and were included in safety and efficacy analyses: 77 patients in the standard GVHD prophylaxis group and 90 in the triple-drug group. At the time of analysis, median follow-up was 48 months (IQR 31-60). The cumulative incidence of grade 2-4 acute GVHD at day 100 was lower in the triple-drug group compared with the standard GVHD prophylaxis group (26% [95% CI 17-35] in the triple-drug group vs 52% [41-63] in the standard group; HR 0·45 [95% CI 0·28-0·73]; p=0·0013). After 1 and 4 years, non-relapse mortality increased to 4% (95% CI 0-9) and 16% (8-24) in the triple-drug group and 16% (8-24) and 32% (21-43) in the standard group (HR 0·48 [0·26-0·90]; p=0·021). Overall survival at 1 year was 86% (95% CI 78-93) in the triple-drug group and 70% in the standard group (60-80) and at 4 years it was 64% in the triple-drug group (54-75) and 46% in the standard group (34-57%; HR 0·62 [0·40-0·97]; p=0·035). Progression-free survival at 1 year was 77% (95% CI 68-85) in the triple-drug group and 64% (53-74) in the standard drug group, and at 4 years it was 59% in the triple-drug group (49-70) and 41% in the standard group (30-53%; HR 0·64 [0·42-0·99]; p=0·045). We observed no difference in the cumulative incidence of grade 3-4 acute GVHD (2% [0-5] in the triple-drug group vs 8% [2-14] in the standard group; HR 0·55 [0·16-1·96]; p=0·36) and chronic GVHD (49% [39-59] in triple-drug group vs 50% [39-61] in the standard group; HR 0·94 [0·62-1·40]; p=0·74). In both groups the most common CTCAE grade 4 or higher toxic effects were pulmonary. INTERPRETATION: Adding sirolimus to cyclosporine and mycophenolate mofetil resulted in a significantly lower proportion of patients developing acute GVHD compared with patients treated with cyclosporine and mycophenolate mofetil alone. Based on these results, the combination of cyclosporine, mycophenolate mofetil, and sirolimus has become the new standard GVHD prophylaxis regimen for patients treated with non-myeloablative conditioning and HLA-matched unrelated HSCT at the Fred Hutchinson Cancer Research Center. FUNDING: National Institutes of Health.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Sandmaier BM, Kornblit B, Storer BE, et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019. PMID: 31248843. doi:10.1016/S2352-3026(19)30088-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。